Abstract
Chronic secondary lymphedema is a potentially devastating condition affecting 90-150 million people worldwide. In the US, lymphedema is most commonly encountered in the upper extremity of women who have undergone axillary lymph node dissection for staging and treatment of breast cancer, though it may also occur following lymph node dissection for melanoma as well as certain gynecology oncologic operations. While a great deal has been elucidated about the biology of lymphatics, lymphatic development, and the lymphatic system in the past 20 years, considerably less is known about impaired lymphatic regeneration and the mechanisms that lead to secondary lymphedema. This deficit in knowledge presents a barrier to the development of effective treatments or prophylactic measures for chronic secondary lymphedema. Recent advances in this arena have showed that pathogenesis of lymphedema is complex, and that effective treatments for this often devastating condition will likely require the use of multiple modalities. In this review, we will discuss the development, anatomy, and physiology of lymphatics as means of introducing this system to the reader. Further, the latest advances in the scientific exploration of lymphedema and lymphatic regeneration will be presented.
Keywords: Lymphatic regeneration, lymphedema, wound
Current Cancer Therapy Reviews
Title: Cellular and Molecular Mechanisms of Lymphangiogenesis and Lymphedema
Volume: 5 Issue: 1
Author(s): Tomer Avraham, Peter J. Quartararo, Sanjay V. Daluvoy and Babak J. Mehrara
Affiliation:
Keywords: Lymphatic regeneration, lymphedema, wound
Abstract: Chronic secondary lymphedema is a potentially devastating condition affecting 90-150 million people worldwide. In the US, lymphedema is most commonly encountered in the upper extremity of women who have undergone axillary lymph node dissection for staging and treatment of breast cancer, though it may also occur following lymph node dissection for melanoma as well as certain gynecology oncologic operations. While a great deal has been elucidated about the biology of lymphatics, lymphatic development, and the lymphatic system in the past 20 years, considerably less is known about impaired lymphatic regeneration and the mechanisms that lead to secondary lymphedema. This deficit in knowledge presents a barrier to the development of effective treatments or prophylactic measures for chronic secondary lymphedema. Recent advances in this arena have showed that pathogenesis of lymphedema is complex, and that effective treatments for this often devastating condition will likely require the use of multiple modalities. In this review, we will discuss the development, anatomy, and physiology of lymphatics as means of introducing this system to the reader. Further, the latest advances in the scientific exploration of lymphedema and lymphatic regeneration will be presented.
Export Options
About this article
Cite this article as:
Avraham Tomer, Quartararo J. Peter, Daluvoy V. Sanjay and Mehrara J. Babak, Cellular and Molecular Mechanisms of Lymphangiogenesis and Lymphedema, Current Cancer Therapy Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339409787314063
DOI https://dx.doi.org/10.2174/157339409787314063 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology Quantitative Structure Activity Relationship (QSAR) Analysis of Substituted 4-Oxothiazolidines and 5-Arylidines as Lipoxygenase Inhibitors
Mini-Reviews in Medicinal Chemistry Cancer and Stem Cells
Current Cancer Therapy Reviews Colon as Target for Drug Delivery
Current Drug Therapy Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Glycomics: Relevance for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Preclinical Toxicity of Paclitaxel Biopolymer Formulation
Anti-Cancer Agents in Medicinal Chemistry Smart Nanocarriers for Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Ubiquitylation and Cancer Development
Current Cancer Drug Targets In Silico Elucidation of the Plausible Inhibitory Potential of Withaferin A of Withania Somnifera Medicinal Herb Against Breast Cancer Targeting Estrogen Receptor
Current Pharmaceutical Biotechnology Nutrigenomics: Advances, Opportunities and Challenges in Understanding the Nutrient-Gene Interactions
Current Nutrition & Food Science Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Current Cancer Therapy Reviews Molecular Bases of Chemoresistance in Cholangiocarcinoma
Current Drug Targets Gene Expression Studies in Multiple Sclerosis
Current Genomics